Apyx Medical (NASDAQ:APYX) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Apyx Medical (NASDAQ:APYX) from a hold rating to a buy rating in a research report released on Thursday morning, Zacks.com reports. They currently have $7.50 target price on the stock.

According to Zacks, “Apyx Medical Corporation is an energy technology company. It provides products in the cosmetic and surgical markets. The company’s Helium Plasma Technology is marketed and sold as Renuvion(R) in the cosmetic surgery market and J-Plasma(R) in the hospital surgical market. Apyx Medical Corporation, formerly known as Bovie Medical Corporation, is based in FL, United States. “

A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of China Southern Airlines from a hold rating to a sell rating in a report on Monday, April 29th. Dougherty & Co dropped their price objective on shares of Apyx Medical from $12.00 to $9.00 and set a buy rating on the stock in a report on Tuesday, April 2nd. Piper Jaffray Companies dropped their price objective on shares of Apyx Medical to $7.00 and set an overweight rating on the stock in a report on Wednesday, May 8th. TheStreet lowered shares of Tribune Publishing from a c- rating to a d+ rating in a report on Monday, May 20th. Finally, JMP Securities set a $146.00 price objective on shares of Hubbell and gave the company a buy rating in a report on Tuesday, April 2nd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Apyx Medical has an average rating of Buy and an average price target of $7.88.

Shares of APYX opened at $6.31 on Thursday. The stock has a market capitalization of $214.03 million, a price-to-earnings ratio of -21.76 and a beta of 0.11. Apyx Medical has a 1-year low of $3.55 and a 1-year high of $8.89. The firm’s fifty day moving average is $6.49.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $5.82 million for the quarter. Apyx Medical had a net margin of 224.06% and a negative return on equity of 12.25%. As a group, equities research analysts anticipate that Apyx Medical will post -0.69 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Rehmann Capital Advisory Group acquired a new position in shares of Apyx Medical in the first quarter worth about $61,000. Menta Capital LLC acquired a new position in shares of Apyx Medical in the first quarter worth about $65,000. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Apyx Medical in the first quarter worth about $66,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Apyx Medical in the first quarter worth about $68,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Apyx Medical in the second quarter worth about $79,000. Institutional investors own 45.53% of the company’s stock.

About Apyx Medical

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Featured Story: What does a dividend yield signify to investors?

Get a free copy of the Zacks research report on Apyx Medical (APYX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.